Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin.
Four of five infants and young children with acute monoblastic leukemia, a disease that heretofore has been highly refractory to therapy, were successfully treated with sequential infusions of a podophyllin derivative employed as a single agent over a protracted period of time. In three of the five children, monocytic leukemia cutis was present at birth. Treatment was begun in two of them when the disease had progressed to systemic involvement at a few months of age, and in the third when disease was still localized. The other two children were 11 and 18 months of age at initial presentation with widespread disease. Four children are off therapy 11 months, 26 months, 5 years, and 6 years, respectively.
D000505:Alopecia / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000139:chemically induced; D004155:Diphenhydramine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000517:prevention & control; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D004155:Diphenhydramine; D011034:Podophyllotoxin